-
Nov 14, 2024 | 
healthaffairs.org | Zachary Baron |Andrew Twinamatsiko |Sheela Ranganathan
The recent election results will usher in sweeping changes for major federal health care policies, programs, and the courts. Donald Trump’s second term in office will diverge substantially from the policies supported by the Biden Administration and will enable the new Administration to pursue aggressive regulatory changes and other measures in the health care arena.
-
Sep 19, 2024 | 
healthaffairs.org | Andrew Twinamatsiko |Zachary Baron
A group of 19 Republican state attorneys general, led by Kris Kobach of Kansas, recently brought a lawsuit challenging the new HHS rule that extends access to health coverage to Deferred Action for Childhood Arrivals (DACA) recipients. A previous Health Affairs Forefront article explained the rule in more detail. The lawsuit, which was filed in a federal district court in North Dakota on August 8, 2024, but then amended on August 28, has been assigned to Judge Daniel M. Traynor, a Trump appointee.
-
Jul 19, 2024 | 
healthaffairs.org | Zachary Baron |Sheela Ranganathan |Andrew Twinamatsiko |Sara Rosenbaum
During its 2024 term, the Supreme Court issued multiple decisions that fundamentally reshape the relationship between the branches of the federal government. Much attention has been paid to its decision in two consolidated cases, Loper Bright Enterprises v. Raimondo and Relentless v. Department of Commerce (collectively "Loper"), in which the Supreme Court effectively declared “Chevron deference” dead.
-
Jun 28, 2024 | 
healthaffairs.org | Zachary Baron |Andrew Twinamatsiko
On June 21, 2024, a Fifth Circuit Court of Appeals panel issued a ruling in Braidwood Management, Inc., v. Becerra, a lawsuit challenging the Affordable Care Act’s (ACA) requirement that insurers and employers cover a broad array of preventive services without cost-sharing.
-
Jun 21, 2024 | 
healthaffairs.org | Andrew Twinamatsiko |Sheela Ranganathan
On June 13, 2024, the Supreme Court rejected a challenge to FDA’s approval of medication abortion, shunting aside one of the latest efforts to impede access to safe abortion after the Supreme Court abrogated the constitutional right to abortion in Dobbs v. Jackson Women’s Health organization.
-
Apr 29, 2024 | 
healthaffairs.org | Sheela Ranganathan |Andrew Twinamatsiko
On April 26, 2024, the Office for Civil Rights (OCR) in the US Department of Health and Human Services (HHS) final rule to strengthen privacy protections for people accessing and providing reproductive health care. The final rule modifies the Standards for Privacy of Individually Identifiable Health Information (Privacy Rule) under the Health Insurance Portability and Accountability Act (HIPAA) and the Health Information Technology for Economic and Clinical Health Act (HITECH Act).
-
Apr 8, 2024 | 
msn.com | Andrew Twinamatsiko |Sheela Ranganathan |Lawrence O. Gostin
Continue reading More for You
-
Sep 20, 2023 | 
jamanetwork.com | Lawrence O. Gostin |James Hodge |Andrew Twinamatsiko
On August 29, 2023, the Biden administration announced the first 10 drugs whose prices will be negotiated with pharmaceutical companies through the Centers for Medicare & Medicaid Services (CMS).1 CMS’ initial list features drugs that are among the most commonly used and highest in total spending in Medicare Part D, including treatments for blood clots (apixaban [Eliquis] and rivaroxaban [Xarelto]), diabetes (empagliflozin [Jardiance] and sitagliptin [Januvia]), cardiovascular disease, and...
-
Sep 20, 2023 | 
jamanetwork.com | Lawrence O. Gostin |James Hodge |Andrew Twinamatsiko
On August 29, 2023, the Biden administration announced the first 10 drugs whose prices will be negotiated with pharmaceutical companies through the Centers for Medicare & Medicaid Services (CMS).1 CMS’ initial list features drugs that are among the most commonly used and highest in total spending in Medicare Part D, including treatments for blood clots (apixaban [Eliquis] and rivaroxaban [Xarelto]), diabetes (empagliflozin [Jardiance] and sitagliptin [Januvia]), cardiovascular disease, and...
-
Sep 13, 2023 | 
healthaffairs.org | Andrew Twinamatsiko |Zach Baron
As we have covered in previous articles here, the new authority Congress provided to the Department of Health and Human Services (HHS) under the Inflation Reduction Act (IRA) to directly negotiate the price Medicare pays for a few high-cost drugs is facing a concerted legal attack by drug manufacturers and their allies. Nine lawsuits challenging the IRA’s negotiation program have so far been filed across the country.
